Cell culture bioreactors
Cell Culture

We work with most cell lines used for manufacturing monoclonal antibodies and recombinant proteins, including CHO, NS/0, BHK, 293 as well as murine hybridomas, and all selection systems used with these lines.
We have also worked with several different selection systems such as dhfr / methotrexate CHO, mycophenolic acid/xanthine, and G418 systems. Our experience includes attached or surface dependent as well as suspension culture types.

For more information, click here.



For the latest GBI news click here.
For additional information, please contact us:
954-327-9656
800-814-8600 Ext 156

info@GoodwinBio.com

Have You Heard?

While confidentiality is paramount at GBI, every once in awhile we have the opportunity to share some significant milestones.

Press Releases


>April 2013 - Goodwin Biotechnology and Coldstream Laboratories Announce a Collaboration to Develop and Manufacture Cytotoxic Antibody Drug Conjugates

>October 2012 - Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards

>June 2012 – Goodwin Biotechnology and MD Anderson Cancer Center Collaborate on the GMP Manufacturing of a Fusion Protein Conjugate that Potentially Represents a Critical Advance in Oncology

>January 2012 - Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a “Bench-to-Clinic” Collaboration for an Important Advance in Oncology

>November 2011 - ImmunoSite Technologies Allies with Goodwin Biotechnology Increasing Capabilities

>October 2011- Goodwin Biotechnology Announces a Collaboration with Spectros Corporation

>June 2011 - Goodwin Biotechnology Announces a Collaboration with Alethia Biotherapeutics

>October 2010 - Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement

> February 2010 - Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration

> September 2009 - Goodwin Biotechnology Inc. Completes cGMP Manufacturing of AREVA Med’s Conjugate

> May 2009 - AREVA Med LLC Selects Goodwin Biotechnology Inc. As A Partner For Its New Cancer Treatment

> January 2009 - Goodwin Biotechnology, Inc. Completes GMP Manufacturing of Neogenix Oncology, Inc. Monoclonal Antibody For Upcoming Clinical Trials

> December 2008 - Goodwin Biotechnology Inc. Completes Development Of AREVA’s New Cancer Treatment

> July 2008 - Goodwin Biotechnology's Manufactured Melanin-Binding Antibody Used in Successful Melanoma Trial

> June 2008 - AREVA Selects Goodwin Biotechnology Inc. As a Partner for Its New Cancer Treatment

> April 2008 - Goodwin Biotechnology, Inc. Completes Major Expansion Project

> March 2008 - Q Therapeutics selects Goodwin Biotechnology for manufacturing of its IgM

> July 2007 - Goodwin Biotechnology and Menarini Announce the Successful Completion of their Strategic US-Italian Cooperation to Fight Ovarian Cancer

> June 2007 - Neogenix Oncology, Inc. Selects Goodwin Biotechnology, Inc. for Manufacturing of its Monoclonal Antibody

> May 2007 - Goodwin Biotechnology Doubles GMP Manufacturing Space

> October 2006 - Goodwin Biotechnology, Inc. named third fastest growing technology company

> October 2006 - Caprion Pharmaceuticals Inc. and Goodwin Biotechnology, Inc. announce a manufacturing partnership for Caprion’s product to fight Shigatoxin-producing E.coli infections

> January 2006 - Goodwin Biotechnology Kicks off Phase III Compliant Expansion

> December 2004 - Goodwin Biotechnology, Inc. Secures Funding for Growth

HOME  |  SITEMAP   |   CONTACT US

© Copyright 2013 | Goodwin Biotechnology, Inc.